An immunoglobulin M (IgM) antibody capture enzyme immunoassay (MAC-EIA) 
LaCrosse (LAC) virus remains a major cause of arboviral encephalitis in the United States (15) . Rapid diagnosis of LAC virus infections is of value to physicians because of similarities in clinical presentation with other encephalitides (1) . Rapid diagnosis of an LAC virus infection would preclude other unnecessary and perhaps invasive diagnostic procedures (for example, brain biopsy in suspected herpesvirus encephalitis) and would assist the physician in prescribing patient care (1, 7, 12) .
Conventional diagnostic tests such as complement fixation, hemagglutination inhibition, and virus neutralization (NT) typically require acute-and convalescent-phase serum specimens to obtain a diagnosis (5) . In addition, these tests usually are performed in centralized facilities such as state laboratories of hygiene, which further delays provision of diagnostic results to physicians.
provides rapid and clinically relevant diagnostic capability for LAC virus infections. However, even stronger serological evidence of etiology is provided by detection of specific IgM in cerebrospinal fluid (CSF). Since specific IgM does not normally cross the blood-brain barrier, the presence of specific IgM in CSF is indicative of virus replication in the central nervous system (CNS) (4, 8, 9, 13, 19) . In terms of rapid diagnosis of CNS infections, examination of CSF offers other advantages. CSF is a less complex clinical specimen than serum, reducing problems with extraneous proteins, rheumatoid factor (6) , and IgM specific for other agents which may not have caused CNS infection. Thus, CSF can be assayed in more concentrated form than serum. In addition, CSF specimens are frequently obtained immediately upon admission from patients with CNS dysfunction.
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In some instances, this may be up to 24 h before blood samples are obtained.
Because of these considerations, we investigated the potential of an MAC-EIA for diagnosis of LAC virus infections by examination of CSF specimens.
MATERIALS AND METHODS
Antigen preparation. The procedure for preparation of a whole virion antigen was similar to that previously published (10) 12 h to enhance suspension. The next day the suspensions were cleared of undissolved debris with low-speed centrifugation at 5,000 x g for 15 min. The supernatant was saved, and the pellet was suspended, lightly mixed on a vortex apparatus, and centrifuged again. This procedure was repeated to enhance virus recovery from the polyethylene glycol pellet. The supernatants were then pooled and further purified by pelleting through a 20% sucrose cushion by ultracentrifugation at 111,000 x g for 2 h. This pellet was then suspended in 1.0 ml of STE buffer and stored overnight at 4°C to enhance the suspension. The virus and control samples were then carefully layered onto 45% potassium tartrate-30% glycerol gradients. The samples were centrifuged at 82,500 x g for 4 h at 4°C. The resulting visible virus band and a "pseudoband" [(-) antigen sample from a tube location with a density corresponding to the position of the (+) virus band] were removed. The bands were then diluted to a concentration of less than 10% potassium tartrate and pelleted at 111,000 x g for 3 h at 4°C. The resulting pellets were suspended in approximately 0.5 ml of STE buffer, dispensed in 0.1-and 0.2-ml volumes, and stored at -70°C. The mean virus titer of the (+) antigens was 7.7 log10 50% tissue culture infectious doses per ml; no infectious virus was detected in the (-) antigen. The protein concentration of the (+) antigen was estimated with a Bio-Rad protein assay to be 0.17 mg of protein per ml; the (-) antigen was 0.05 mg of protein per ml.
Antibody preparation. Antibodies to LAC virus were prepared by immunization of a rabbit. The rabbit was inoculated intramuscularly with a suspension of approximately 4.5 logl0 50% tissue culture infectious doses of stock (plaque-purified) LAC virus in 1.0 ml. On days 35 and 55 the rabbit was inoculated intramuscularly (1.0 ml) with approximately 5.5 log10 50% tissue culture infectious doses of gradient-purified LAC virus. The rabbit was then bled 8 days later, and the serum was found to have an anti-LAC virus titer of -1:2,560 by indirect fluorescent antibody staining (2) .
The antibodies were then separated from the serum by ammonium sulfate precipitation (17) . After two successive 50% fractionations at 4°C, antibodies were suspended in phosphate-buffered saline (PBS) and dialyzed with PBS buffer; both precipitations were done at pH 7.3. The protein concentration of this suspension, as determined with the Bio-Rad protein assay, was approximately 15 mg/ml.
Test specimen selection. The paired acute serum and CSF specimens were selected from stored (-70°C) samples obtained from patients who had symptoms compatible with encephalitis at the Gundersen Clinic LaCrosse-Lutheran Hospital (LLH) during the arboviral seasons of 1979 through 1983. In general, both CSF and acute-phase serum specimens were obtained upon the day or within 1 day of admission. The samples ranged from 0 to 14 days after onset of symptoms, with a mean of 3.9 days. Exclusion of one sample obtained 14 days after onset of symptoms resulted in a mean of 3.4 days.
A total of 108 paired acute-phase serum and CSF samples were studied. Serum specimens from certain of these patients had previously been examined by the Sensitivity and specificity of MAC-EIA. The sensitivity of the MAC-ETA was compared with the diagnostic results from LLH, the Virology Section of the State Laboratory of Hygiene, and the Zoonoses Research Unit, as described above. The diagnostic efficacy of the MAC-EIA and M-IF tests using serum and CSF specimens was compared. In addition, the sensitivity and specificity of MAC-EIA diagnosis of LAC infections by examination of CSF were determined by using the results of MAC-EIA examination of serum as the referent standard (11) . The false-negative rate was calculated as 1 minus sensitivity; the false-positive rate was calculated as 1 minus specificity.
RESULTS

Detection of LAC virus IgM in serum.
Of the 108 patient serum specimens tested, 28 were from patients who had been serologically confirmed as having LAC virus infection. All 28 specimens were positive by the MAC-EIA. In addition, the MAC-EIA detected anti-LAC IgM antibodies in the serum specimens of two patients whose cases had not been serologically confirmed previously. Both of these patients had been scored as questionable in the M-IF test conducted upon admission at LLH. Since both were discharged within several days after admission, convalescent sera were not obtained, and samples had not been sent to the State Laboratory of Hygiene for testing by hemagglutination inhi- bition or NT. Thus neither patient had been confirmed as having an LAC virus infection. These two specimens were subsequently demonstrated to contain NT antibody to LAC virus and were thus considered to be confirmed cases for these analyses. Therefore, of the 108 patient CSF and serum specimen pairs, 30 were considered to be from patients with confirmed LAC virus infections.
The serum specimen from the patient who experienced an LAC virus infection 4 years previously was negative by MAC-EIA. One patient, who was diagnosed as having a JC virus infection by NT, was tested twice in the LAC MAC-EIA; negative results were obtained on both occasions. There were two additional patients in the study who had detectable serum NT antibody to JC virus; both were negative in the LAC virus MAC-EIA.
The MAC-EIA detected IgM antibody to LAC virus in the acute-phase serum specimen of 100% (30 of 30) of the confirmed LAC virus infections (Table 1) . When the same serum specimens were examined by M-IF upon presentation at LLH, 70% (21 of 30) had contained detectable anti-LAC virus IgM (Table 1 Positive  27  0  27  Negative  3  30  33  Total  30  30  60 a Sensitivity, 0.90; specificity, 1.0; false-negative, 0.10; false-positive, 0.0.
The sensitivity rate of the CSF MAC-EIA was 0.90; the specificity rate was 1.0 (Table 2) . DISCUSSION The sensitivity of the MAC-EIA for diagnosis of LAC virus infections in these specimens was surprising; 100% (30 of 30) of the patients with confirmed LAC infections were diagnosed with the acute-phase serum specimen. In a previous study, a similar MAC-EIA diagnosed 83% (24 of 29) of the cases with the acute phase specimens (14) . Whether the increased sensitivity is due to fortuitous selection of patient specimens or to alterations in the MAC-EIA protocol has not been addressed. In regard to the latter possibility, major differences in the EIA test protocol used herein were removal of the N-acetylcysteine treatment and the use of normal goat serum instead of bovine serum in the blocking step and in certain diluents. The use of goat serum (the anti-human IgM was prepared in goats) proved most effective in reducing background noise (data not shown).
The MAC-EIA proved to be a sensitive technique for detection of IgM in CSF; IgM was detected in 27 of 30 (90%) confirmed positive cases. In contrast IgM was only detected in 3 of 30 (10%) samples by M-IF even though a fivefold more concentrated sample was examined. A number of the patients had detectable IgM in the serum and the CSF on the day of presentation (data not shown).
In general, CSF results were concordant (27 of 30) with those obtained from serum samples. Thus anti-LAC IgM is detectable in the CSF of most children who are hospitalized as a consequence of infection with LAC virus. Of the three discordant CSF specimens, two were scored as equivocal, and one was scored as negative. The patients with equivocal cases did not have unusual case histories, and in the absence of other serological information they would not have been diagnosed. However, both had detectable IgM in their serum specimens; thus these patients were diagnosed as having LAC virus infections. If the diagnostic criteria had been less stringent (i.e., the mean plus two standard deviations), both would have been diagnosed as positive. In the third case, the serum MAC-EIA was scored as a weak positive, and the CSF MAC-EIA was negative.
JC virus, a California group virus related to LAC virus, has recently been recognized to cause significant morbidity in humans (18) . Three patients examined in these studies had antibodies to JC virus. In one case, there was a demonstrable increase in NT antibody titer to JC virus between acute and convalescent serum specimens. In the other two cases, NT antibody titers did not change, suggesting that these two patients had been infected with JC virus before the current disease episode. None of these three cases was falsely identified as LAC virus infection by the MAC-EIA. Of course, the previous infections would be unlikely to be diagnosed.
In approximately 30% (11 of 30) of the cases, the IgM specific activity in the CSF was somewhat greater than that of the respective serum (data not shown). This phenomenon has been noted in the diagnosis of other encephalitides (4, 9 
